🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

NATCO Pharma Limited NATCOPHARM NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.natcopharma.co.in
Company Profile ↓
₹784.45
-11.18% 1Y
Mkt Cap₹14,433.88 Cr
P/E12.38
P/B1.53
Div. Yield0.75%
52W High₹1,203.98
52W Low₹782.65
Book Value₹514.92
EPS (TTM)₹63.37

Company Overview

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 16.3%.

Consistent Profit Growth

Net profit has compounded at 25.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 12.4, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 32.8%.

Recent Developments

  • Mar 2026 Revenue of ₹4,078.30 Cr (-7.9% YoY); net profit ₹1,418.50 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -44.7%, earnings -57.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.8%, profit CAGR 25.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.78%
1 Year:-44.70%

Compounded Profit Growth

5 Years:25.64%
1 Year:-57.00%

Stock Price Performance

1 Year:-11.18%
6 Months:-27.90%
3 Months:-14.46%
1 Month:-3.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
₹782.65 ₹1,203.98
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)37.22 · Neutral
Price Performance
1M-3.11%
3M-14.46%
6M-27.90%
1Y-11.18%
Valuation vs Sector

P/E of 12.38 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 32.8%.
  • Compounding revenue at 14.8% over 5 years.
  • Profit CAGR of 25.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 34.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
12.38
Industry PE
36.43
Forward P/E
16.56
PEG Ratio
-
Book Value
₹514.92
Price to Book
1.53
P/S
4.17
EV/EBITDA
11.99
Dividend Yield
0.75%

Growth (CAGR)

Revenue 5Y
14.78%
Profit 5Y
25.64%
Revenue (YoY)
-44.70%
Earnings (YoY)
-57.00%

Profitability & Returns

ROCE
16.26%
ROE
15.38%
ROA
12.81%
Profit Margin
32.84%
Op Margin
18.96%
Gross Margin
82.64%
EPS (Latest Qtr)
₹14.96
EPS (TTM)
₹63.37

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
2.47
Current Ratio
3.01
Debt
₹713.90 Cr
Total Assets
₹11,073.70 Cr
Current Assets
₹5,052.30 Cr
Working Capital
₹3,371.40 Cr

Ownership

Promoter Holding
50.88%
Chg in Prom Hold
-0.07%
FII / Inst Holding
12.99%
Chg in FII Hold
-0.03%

Financial Snapshot

Enterprise Value
₹14,433.88 Cr
Total Revenue (TTM)
₹3,484.60 Cr
EBITDA
₹1,069.65 Cr
Free Cash Flow
₹1,377.20 Cr
Operating Cash Flow
₹1,768.30 Cr
Shares Outstanding
₹18.40 Cr
Gross Margin
82.64%
Payout Ratio
7.83%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NATCOPHARM NATCO Pharma Limited NIFTY_SMALLNSEPHARMA 784.45 12.38 ₹14,433.88 Cr 0.75% 16.26% 15.38% 14.78% 25.64%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 898.00 Cr1,140.00 Cr1,031.00 Cr759.00 Cr1,068.00 Cr1,363.00 Cr1,371.00 Cr475.00 Cr1,221.00 Cr1,328.90 Cr1,363.00 Cr647.30 Cr739.10 Cr
Cost of Revenue --------249.20 Cr233.00 Cr169.70 Cr133.10 Cr154.70 Cr
Gross Profit --------971.80 Cr1,095.90 Cr1,193.30 Cr514.20 Cr584.40 Cr
Operating Expenses 559.00 Cr612.00 Cr573.00 Cr490.00 Cr571.00 Cr558.00 Cr567.00 Cr436.00 Cr522.00 Cr582.50 Cr666.50 Cr401.70 Cr507.20 Cr
Operating Income 298.00 Cr484.00 Cr414.00 Cr224.00 Cr441.00 Cr761.00 Cr758.00 Cr-8.00 Cr449.80 Cr513.40 Cr526.80 Cr112.50 Cr77.20 Cr
EBITDA 339.00 Cr528.00 Cr458.00 Cr268.00 Cr497.00 Cr805.00 Cr804.00 Cr39.00 Cr614.40 Cr632.70 Cr679.20 Cr216.80 Cr205.40 Cr
Interest Expense 3.00 Cr4.00 Cr4.00 Cr5.00 Cr6.00 Cr5.00 Cr4.00 Cr4.00 Cr10.20 Cr3.20 Cr13.10 Cr9.50 Cr10.90 Cr
Pretax Income 324.00 Cr500.00 Cr440.00 Cr256.00 Cr478.00 Cr804.00 Cr818.00 Cr164.00 Cr505.90 Cr571.90 Cr613.70 Cr161.10 Cr144.10 Cr
Tax Provision 48.60 Cr80.00 Cr70.40 Cr43.52 Cr90.82 Cr136.68 Cr139.06 Cr31.16 Cr99.90 Cr91.60 Cr95.80 Cr20.70 Cr-89.20 Cr
Net Income 276.00 Cr420.00 Cr369.00 Cr213.00 Cr386.00 Cr668.00 Cr676.00 Cr132.00 Cr406.60 Cr480.70 Cr518.40 Cr151.50 Cr267.90 Cr
Diluted EPS 15.1123.4720.6011.8821.5737.3237.817.4322.7026.8428.948.4614.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 825.00 Cr1,042.00 Cr2,020.00 Cr2,185.00 Cr2,094.00 Cr1,915.00 Cr2,052.00 Cr-2,696.90 Cr3,978.80 Cr4,429.50 Cr4,078.30 Cr
Cost of Revenue --------745.50 Cr862.50 Cr689.80 Cr690.50 Cr
Gross Profit --------1,951.40 Cr3,116.30 Cr3,739.70 Cr3,387.80 Cr
Operating Expenses 615.00 Cr777.00 Cr1,337.00 Cr1,256.00 Cr1,300.00 Cr1,332.00 Cr1,446.00 Cr-1,161.30 Cr1,539.50 Cr1,778.90 Cr2,157.90 Cr
Operating Income 163.00 Cr215.00 Cr629.00 Cr862.00 Cr714.00 Cr483.00 Cr489.00 Cr-790.10 Cr1,576.80 Cr1,960.80 Cr1,229.90 Cr
EBITDA 210.00 Cr266.00 Cr683.00 Cr928.00 Cr795.00 Cr583.00 Cr606.00 Cr-1,035.20 Cr1,872.30 Cr2,550.50 Cr1,734.10 Cr
Interest Expense 32.00 Cr23.00 Cr18.00 Cr15.00 Cr19.00 Cr22.00 Cr13.00 Cr-9.50 Cr12.00 Cr23.90 Cr36.70 Cr
Pretax Income 132.00 Cr204.00 Cr624.00 Cr887.00 Cr825.00 Cr569.00 Cr580.00 Cr-861.90 Cr1,673.50 Cr2,291.40 Cr1,490.80 Cr
Tax Provision 1.32 Cr48.96 Cr137.28 Cr195.14 Cr181.50 Cr108.11 Cr139.20 Cr-146.60 Cr285.20 Cr408.00 Cr118.90 Cr
Net Income 130.00 Cr156.00 Cr485.00 Cr695.00 Cr642.00 Cr458.00 Cr442.00 Cr-715.30 Cr1,388.30 Cr1,885.40 Cr1,418.50 Cr
Diluted EPS 8.109.0227.8837.7435.2425.3124.189.3239.1877.34105.26-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,384.00 Cr1,822.00 Cr2,318.00 Cr3,715.00 Cr4,303.00 Cr4,588.00 Cr4,792.00 Cr-5,657.40 Cr6,906.30 Cr8,630.80 Cr11,073.70 Cr
Current Assets --------3,000.30 Cr4,023.50 Cr5,270.00 Cr5,052.30 Cr
Cash & Equivalents --------131.90 Cr70.40 Cr120.00 Cr198.90 Cr
Inventory --------742.90 Cr700.50 Cr765.80 Cr908.50 Cr
Receivables --------856.10 Cr1,188.90 Cr1,246.60 Cr881.20 Cr
Total Liabilities --------783.60 Cr1,053.20 Cr1,018.50 Cr1,852.60 Cr
Current Liabilities --------683.10 Cr972.80 Cr943.50 Cr1,680.90 Cr
Long Term Debt -----------100.00 Cr
Total Debt 312.00 Cr113.00 Cr222.00 Cr173.00 Cr386.00 Cr316.00 Cr268.00 Cr-176.10 Cr371.20 Cr279.40 Cr713.90 Cr
Total Equity 846.00 Cr1,296.00 Cr1,649.00 Cr3,072.00 Cr3,488.00 Cr3,773.00 Cr4,121.00 Cr-4,873.80 Cr5,853.10 Cr7,607.00 Cr9,221.10 Cr
Shares Outstanding --------18.26 Cr17.91 Cr17.91 Cr17.91 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 93.00 Cr112.00 Cr346.00 Cr464.00 Cr669.00 Cr417.00 Cr299.00 Cr-849.10 Cr1,211.60 Cr1,696.80 Cr1,768.30 Cr
Investing Cash Flow -120.00 Cr-176.00 Cr-299.00 Cr-1,116.00 Cr-611.00 Cr-175.00 Cr-107.00 Cr--477.10 Cr-1,032.70 Cr-1,414.50 Cr-2,081.70 Cr
Financing Cash Flow 29.00 Cr154.00 Cr-48.00 Cr651.00 Cr-51.00 Cr-251.00 Cr-186.00 Cr--363.00 Cr-246.90 Cr-210.70 Cr297.50 Cr
Capital Expenditure -118.00 Cr-156.00 Cr-280.00 Cr-407.00 Cr-444.00 Cr-336.00 Cr-207.00 Cr--205.60 Cr-358.70 Cr-511.60 Cr-391.10 Cr
Free Cash Flow -25.00 Cr-44.00 Cr66.00 Cr57.00 Cr225.00 Cr81.00 Cr92.00 Cr-643.50 Cr852.90 Cr1,185.20 Cr1,377.20 Cr
Net Change in Cash 2.00 Cr90.00 Cr-1.00 Cr-2.00 Cr7.00 Cr-8.00 Cr6.00 Cr-9.00 Cr-68.00 Cr71.60 Cr-15.90 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------72.4%78.3%84.4%83.1%
Operating Margin % 19.8%20.6%31.1%39.5%34.1%25.2%23.8%-29.3%39.6%44.3%30.2%
Net Margin % 15.8%15.0%24.0%31.8%30.7%23.9%21.5%-26.5%34.9%42.6%34.8%
ROE % 15.4%12.0%29.4%22.6%18.4%12.1%10.7%-14.7%23.7%24.8%15.4%
ROCE % --------15.9%26.6%25.5%13.1%

Shareholding Pattern

Insiders
50.88%
Institutions
12.99%
Public Float
26.45%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NATCOPHARM

Google News Mon, 19 Oct 2026

News by CNBC TV18 on TradingView, 2026-10-19 — cnbctv:109ca687f094b:0 - TradingView

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1vNnNkVE1ObWkzblExc1BxcEdXV2x6czA2N19ETktQek82U2pMbGpycGpZajQ4VjBncEdkR3hqeTU3YmFYc3BqUGgyODdYWEMxNlZBXzlJNy1FbXVCaG92VFVaekVMMmM?oc=5" target="_blank">News by CNBC TV18 on Trading…

Google News Fri, 25 Sep 2026

Natco Pharma Plans ₹1,279 Cr Rights Issue at ₹750 - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNb3VDenJiLWtQM1Jkd1JxNndzTUJGV2ttblRLT2lKYzl1NXdvYW84NWNuQmx5SXo1Zk0zdk9rTXpYbmE2V1FRQUVnWExpTldnZUJGTXdTcDhBanVEbjRnY21QaHlZbWpKVHc5ZFFmaEo4V3pyUHVXNW9WY0Fyd25kckRMUHVaYWVKNFFqS0…

Google News Mon, 17 Aug 2026

NATCO Pharma Limited (NSE:NATCOPHARM) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPaEpuR1FRc3NHOEdnaFNJdnlOeFRYQVhaWXZkOGRoZWpyT0dBUmt6RmowYlpNVjJGSE5melN2WDNiZWh5MGlxVllZRW5UcnhTdTVvRG5ucE42c3AyUjljS2FmS2xPOFRqODEwSW9UeDhJSGlzWDFwcnhMVWJhcEYwdkZiWGtYa2hNdWk4Nk…

Google News hu, 22 Oct 2026

Natco Pharma Share Price today near 52-week low: analysis - Univest

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOM0xtRV9Ia0tpTS05dmhTYkJaTWFDelphcTh6bThCTEZ6bXN4Q3QxZkwyVW5CZklHejM0TTZqcmxGdjdCQ2ZFQjFUNWVOSmVqUTJpSmNEcFBPa05KdGFoUGZpTlhWeWNXOXdTODdUQW5OaHRKbUM0V2Rfd29ha0hXVW1fd3dEQmk2VDVXLV…

Google News Fri, 29 May 2026

Natco Pharma shares fall 12% as firm reports 34% drop in Q4 net profit at Rs 268 crore - TradingView

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQaXg0RjR4Tm1LWndaS3E5dW1rdnBSZGNydDZ1V2RPQ2xlSU9nX0lyaFRHVVA5WkRzZzNlZktyYzZBb2lZTHBJZDBublpabDNLbVRIY1VmT0R2RlZncDVEZzFEUzBWb3VvZTQzMzdsNVRPeDJyYXBBMzE1WTZBSllORGQ3YlBHeTE4Z0padn…

Google News hu, 22 Oct 2026

NATCO Pharma Rights Issue Closes 22 Oct 2026 - Kalkine India

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPNHJnbkZNM0NILUFPcDhOMHZZbWRKYzY2alVwVXE2VllTYXA0Q094c1BGMnplX1hhREhwUERYSW1KcDcxV3l4UmdCeDJ5Rl9zb29CVjUxWHJrZUNEaXhyeGNCMkpnOGYyUzNEZGlheWpWWlJxcnRKTDFuY0VuZ0JPTzFERDRLZEh4WmxLa0…

NATCOPHARM — Frequently Asked Questions

What is the current share price of NATCO Pharma Limited (NATCOPHARM)?

As of 2026-10-23 04:58 IST, NATCO Pharma Limited (NATCOPHARM) trades at ₹784.45 on NSE. Its 52-week range is ₹782.65 to ₹1,203.98.

What is the market capitalisation of NATCOPHARM?

NATCO Pharma Limited (NATCOPHARM) has a market capitalisation of ₹14,433.88 Cr on NSE.

What is the P/E ratio of NATCOPHARM?

NATCOPHARM trades at a trailing price-to-earnings (P/E) ratio of 12.38. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 1.53.

Does NATCOPHARM pay a dividend?

NATCO Pharma Limited (NATCOPHARM) currently offers a dividend yield of 0.75%.

What is the return on equity (ROE) of NATCOPHARM?

NATCOPHARM has a return on equity (ROE) of 15.38%. Its return on capital employed (ROCE) is 16.26%.

Is NATCOPHARM a good stock to buy?

This page provides a data-driven analysis of NATCO Pharma Limited (NATCOPHARM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space